The Inovio Pharmaceuticals (NASDAQ: INO) stock has been quite volatile in recent times but late on Monday, the stock got a significant boost after the company announced its fourth-quarter results. On top of that, Inovio also provided an update on its product that is meant for treating pre-cancerous lesions.
The losses for the quarter came in at 14 cents a share and that was not only lower than analysts’ estimates of 22 cents a share but also lower than the 38 cents a share loss Inovio made a year ago.
On the other hand, Inovio also revealed positive data with regards to its product as mentioned above. The REVEAL 1 trial of the product showed that the product managed to meet both the primary as well as secondary endpoints in patients who had been evaluated. The dual announcement could well prove to be a significant boost for the Inovio stock and hence, investors could consider keeping an eye on the stock today.
Finance and Tech Contributor